MABCURE N.V. Signs Research Agreement With AZ Sint Lucas Hospital, Brugge, Belgium, to Conduct Preclinical Research on its Mo...
November 04 2009 - 12:15PM
Business Wire
MabCure N.V., a subsidiary of MabCure Inc. (OTC BB: MBCI), a
biotech company that has developed a series of highly specific
monoclonal antibodies (Mabs) to combat various types of cancers,
has signed a research agreement with AZ Sint Lucas Hospital,
Brugge, Belgium. AZ Sint Lucas Hospital will conduct preclinical
research intended to broaden the utility of MabCure’s monoclonal
antibodies for those circumstances where there is a need to
diagnose cancer in tissue specimen. At present, the Company’s Mabs
for the diagnosis of ovarian cancer, prostate cancer and colorectal
cancer, for example, are aimed at diagnosing early stage disease in
physiological samples such as urine and serum.
Dr. Amnon Gonenne, CEO of MabCure Inc commented, “If this
preclinical research works, it would open a door for us to diagnose
everything that goes through surgery. This would include, for
example, all of the at-risk melanoma patient population that
routinely has moles removed prophylactically. The resection is
arbitrary and there is currently no method to determine if the
removed moles harbor early stage melanoma or not. This is
critically important since melanoma is a highly lethal disease.
MabCure’s Mabs may provide a definitive diagnosis of early stage
melanoma in these tissue specimens thereby allowing effective
treatment of the patient. An analogous situation exists in
colonoscopy where it is difficult to provide definitive diagnosis
of early colon cancer in the resected polyps. This approach could
be extended to other organs.”
Dr. Gonnene continued, “Currently, we address
multibillion-dollar opportunities with the specimens we know our
Mabs are effective against. This new opportunity would allow us to
cast an even wider net and we are very excited about the
possibility of helping these patients.”
Studies have already begun at AZ Sint Lucas Hospital, and all
scientific results will remain a property of MabCure.
About AZ Sint Lucas Hospital
The Saint Lucas General Hospital in Bruges is an independent
hospital with emphasis on advanced patient care, active clinical
research and participation in multi-center clinical trials.
About MabCure Inc.
MabCure is a biotechnology company whose vision is to change the
perception of cancer as being a largely incurable disease. MabCure
owns proprietary technology for the creation of unique and highly
specific monoclonal antibodies (MAbs), which will be developed as
diagnostic tools, imaging agents, and drugs to treat lethal
cancers. MabCure initial goal is to develop its novel MAbs as
diagnostic tools for the detection of Ovarian and Prostate cancers
at an early stage, when these diseases are still localized and
highly curable. For further information visit the Company’s website
www.mabcure.com.
Safe Harbor Statement
This news release contains “forward-looking statements”.
Statements in this news release which are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the change of business focus of the
management of the Company or the University and the inability of
the Company or the University to pursue its current objectives.
These forward-looking statements are made as of the date of this
news release and the Company or the University assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements.
MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024
MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jul 2023 to Jul 2024
